Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
72.80
-0.79 (-1.07%)
Aug 13, 2025, 4:00 PM - Market closed
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $194.43M in the quarter ending June 30, 2025, with 18.70% growth. This brings the company's revenue in the last twelve months to $716.08M, up 25.71% year-over-year. In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth.
Revenue (ttm)
$716.08M
Revenue Growth
+25.71%
P/S Ratio
10.55
Revenue / Employee
$1,432,160
Employees
500
Market Cap
7.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CORT News
- 6 days ago - Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early - Seeking Alpha
- 12 days ago - Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update - Business Wire
- 20 days ago - Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 4 weeks ago - Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 6 weeks ago - Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators - Seeking Alpha
- 7 weeks ago - Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care - Business Wire
- 2 months ago - Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring - Seeking Alpha